PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3552853-9	1987	Related to a maximum duration of pregnancy of 34 weeks, RDS morbidity after Ambroxol therapy was 18.2% (2 out of 11), as opposed to 35.7% (5 out of 14) after betamethasone treatment.	Ambroxol	76-84	peripherin 2	Homo sapiens	56-59	
8119565-8	1993	Inducing prepartually lung-maturity with glucocorticoides or ambroxol resulted in a significant decrease of the RDS-rate in new born children up to the 34th week of gestation.	Ambroxol	61-69	peripherin 2	Homo sapiens	112-115	
3552853-10	1987	The results confirm that antenatal administration of Ambroxol can bring about a reduction in neonatal RDS corresponding to that achieved with betamethasone therapy.	Ambroxol	53-61	peripherin 2	Homo sapiens	102-105	
6478010-2	1984	The aim of this study was to compare PMN functions in two groups of premature infants whose mothers had received betamethasone or ambroxol for prevention of RDS.	Ambroxol	130-138	peripherin 2	Homo sapiens	157-160	
3515786-1	1986	In a multicenter, randomized double-blind study, the effect of Betamethasone and Ambroxol, both used for prenatal prevention of RDS in premature and newborn infants, is compared in a total of 185 patients with premature labour or an induced termination of pregnancy between the 28 and 36th week of gestation.	Ambroxol	81-89	peripherin 2	Homo sapiens	128-131	
3515786-6	1986	RDS morbidity, established by a standardized evaluation of the infants considering X-ray, clinical and blood-gas analyses findings, is 9% (7 out of 79 infants) in the Ambroxol group, and 6% (5 out of 86 infants) in the Betamethasone group.	Ambroxol	167-175	peripherin 2	Homo sapiens	0-3	
10845438-1	2000	In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia].	Ambroxol	116-124	peripherin 2	Homo sapiens	82-85	
10845438-1	2000	In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia].	Ambroxol	116-124	peripherin 2	Homo sapiens	211-214